Volume 86 Issue 16 | p. 25 | Concentrates
Issue Date: April 21, 2008

Roche will acquire Piramed Pharma

Department: Business | Collection: Sustainability

Roche will pay $160 million to acquire Piramed Pharma, a privately owned U.K. biotech company. Five-year-old Piramed focuses on therapeutics targeting PI 3-kinases, which play roles in disease progression, inflammation, and cancer cell resistance to chemotherapy. Roche will also pay $15 million at the start of Phase II clinical trials for Piramed's oncology drug candidate. Since 2005, Piramed has been developing the compound in collaboration with Genentech, in which Roche holds a majority ownership stake.

 
Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment